Krystof MD - Voyager Therapeutics Founder
| VYGR Stock | USD 5.75 0.06 1.05% |
Insider
Krystof MD is Founder of Voyager Therapeutics
| Address | 75 Hayden Avenue, Lexington, MA, United States, 02421 |
| Phone | 857 259 5340 |
| Web | https://www.voyagertherapeutics.com |
Voyager Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.0157 % which means that it generated a profit of $0.0157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1022 %, meaning that it created $0.1022 on every $100 dollars invested by stockholders. Voyager Therapeutics' management efficiency ratios could be used to measure how well Voyager Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Brittany Mccleery | Sana Biotechnology | N/A | |
| YuWaye MD | Fate Therapeutics | N/A | |
| Reinhard Kandera | Hookipa Pharma | 55 | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Justin Skoble | Caribou Biosciences | N/A | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Prof MD | Hookipa Pharma | 80 | |
| Cindy Hayashi | Caribou Biosciences | N/A | |
| James JD | Karyopharm Therapeutics | N/A | |
| Steven Kanner | Caribou Biosciences | 65 | |
| Mark DVM | Fate Therapeutics | 63 | |
| Robert II | Arcus Biosciences | 51 | |
| Jason MBA | Caribou Biosciences | 56 | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| Edward III | Fate Therapeutics | 48 | |
| Jason Barker | Arcus Biosciences | 49 | |
| MS MBA | Fate Therapeutics | N/A | |
| Jonathan Yingling | Arcus Biosciences | 55 | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
Management Performance
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0157 |
Voyager Therapeutics Leadership Team
Elected by the shareholders, the Voyager Therapeutics' board of directors comprises two types of representatives: Voyager Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Voyager. The board's role is to monitor Voyager Therapeutics' management team and ensure that shareholders' interests are well served. Voyager Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Voyager Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sandrock MD, CEO Pres | ||
| Dr MBA, Chief Officer | ||
| Trista Morrison, Chief CEO | ||
| JD Esq, Chief Officer | ||
| Andre Turenne, President CEO | ||
| Todd Carter, Chief Officer | ||
| Robert Hesslein, Senior Vice President General Counsel | ||
| Robin Swartz, Chief Officer | ||
| Krystof MD, Founder | ||
| Guangping Gao, Founder Board | ||
| Peter CPA, Chief Officer | ||
| Phillip Zamore, Founder Board | ||
| Michelle Smith, Chief Officer |
Voyager Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Voyager Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0157 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | (0.56) % | ||||
| Current Valuation | 14.36 M | ||||
| Shares Outstanding | 54.63 M | ||||
| Shares Owned By Insiders | 16.98 % | ||||
| Shares Owned By Institutions | 65.50 % | ||||
| Number Of Shares Shorted | 2.56 M | ||||
| Price To Earning | 5.62 X |
Pair Trading with Voyager Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Voyager Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Voyager Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Voyager Stock
The ability to find closely correlated positions to Voyager Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Voyager Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Voyager Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Voyager Therapeutics to buy it.
The correlation of Voyager Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Voyager Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Voyager Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Voyager Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.